Botulinum Toxin for Pain

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Drugs in R&D

• Publication date

  2008-01-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2165/00126839-200809010-00002PMID 18095750PMCID PMC7044398
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Botulinum Toxin type A reduces capsaicin‐evoked pain and neurogenic vasodilatation in human skin

  2007influential reference
• Botulinum toxin A for myofascial trigger point injection: A qualitative systematic review

  2007cited by this paper
• More than a cosmetic fix. Combined with physical therapy, botulinum toxin type A can help provide relief for chronic muscle pain.

  2007cited by this paper
• Mild cognitive impairment : Risk of Alzheimer disease and rate of cognitive decline. Authors' reply

  2007cited by this paper
• Botulinum toxin, Quo Vadis?

  2007cited by this paper
• Botulinum toxin type-a in the prevention of migraine: a double-blind controlled trial.

  2007cited by this paper
• A double-blind, controlled study of botulinum toxin a in chronic myofascial pain. Authors' reply

  2007cited by this paper
• Improvement of chronic facial pain and facial dyskinesia with the help of botulinum toxin application

  2007cited by this paper
• Industrial medicine and acute musculoskeletal rehabilitation. 4. Interventional procedures for work-related cervical spine conditions.

  2007cited by this paper
• A double-blind, controlled study of botulinum toxin A in chronic myofascial pain.

  2007cited by this paper
• [Botulinum toxin for the treatment of pain syndromes].

  2006cited by this paper
• Ictal eye closure is a reliable indicator for psychogenic nonepileptic seizures

  2006cited by this paper
• An open label pilot investigation of the efficacy of Botulinum toxin type A [Dysport] injection in the rehabilitation of chronic anterior knee pain

  2006cited by this paper
• Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport®) for the relief of upper back myofascial pain syndrome: Results from a randomized double‐blind placebo‐controlled multicentre study

  2006cited by this paper
• The effects of Botulinum Toxin type A on capsaicin‐evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization

  2006cited by this paper
• A Lack of Antinociceptive or Antiinflammatory Effect of Botulinum Toxin A in an Inflammatory Human Pain Model

  2006cited by this paper
• A double-blind, controlled study of botulinum toxin A in chronic myofascial pain

  2006cited by this paper
• Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome

  2005cited by this paper
• Injections of Botulinum Toxin Type A Produce Pain Alleviation in Intractable Trigeminal Neuralgia

  2005cited by this paper
• Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: A randomised double blind crossover study

  2005cited by this paper
• Botulinum toxin: mechanisms of action.

  2005cited by this paper
• Botulinum Toxin: Mechanisms of Action

  2005cited by this paper
• Botulinum Toxin Type A for the Prophylaxis of Chronic Daily Headache: Subgroup Analysis of Patients Not Receiving Other Prophylactic Medications: A Randomized Double‐Blind, Placebo‐Controlled Study

  2005cited by this paper
• [How botulinum toxin enriches orthopedics. Toxin against contractures and pain].

  2005cited by this paper
• Neurobiological basis for the use of botulinum toxin in pain therapy

  2004influential reference
• Treatment with botulinum neurotoxin of gastrointestinal smooth muscles and sphincters spasms

  2004cited by this paper
• Biomechanics of musculoskeletal pain: dynamics of the neuromatrix.

  2004cited by this paper
• Pathways that elicit long-term changes in gene expression in nociceptive neurons following nerve injury: contributions to neuropathic pain

  2004cited by this paper
• EFFICACY AND SAFETY OF

  2004cited by this paper
• Use of botulinum toxin-A for musculoskeletal pain in patients with whiplash associated disorders [ISRCTN68653575]

  2004cited by this paper
• Botulinum toxin type A (Botox®) in the treatment of migraine and other headaches

  2004cited by this paper
• Different types of botulinum toxin in humans

  2004cited by this paper
• Subcutaneous administration of botulinum toxin A reduces formalin‐induced pain

  2004influential reference
• Regulated Exocytosis Contributes to Protein Kinase C Potentiation of Vanilloid Receptor Activity*

  2004cited by this paper
• Anesthesic agents and procediments in the treatment of muscle pain

  2003cited by this paper
• The pathogenesis of muscle pain

  2003influential reference
• Use of Botulinum Toxin in the Treatment of Chronic Myofascial Pain

  2003cited by this paper
• [Use of botulinum toxin the the treatment of muscle pain].

  2003cited by this paper
• Diffuse noxious inhibitory controls (DNIC) attenuate temporal summation of second pain in normal males but not in normal females or fibromyalgia patients

  2003cited by this paper
• [Acupuncture (dry needle) versus neural therapy (local anesthesia) in the treatment of benign back pain. Immediate and long-term results].

  2003cited by this paper
• Injection therapies for soft-tissue disorders.

  2003cited by this paper
• Botulinum toxin a improved burning pain and allodynia in two patients with spinal cord pathology.

  2003cited by this paper
• Parinaud syndrome heralding MS

  2003cited by this paper
• A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A

  2003influential reference
• Focused review: Botulinum toxin type A therapy in chronic pain disorders

  2003cited by this paper
• Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin

  2003cited by this paper
• Der Einsatz von Botulinumtoxin in der Therapie von Muskelschmerzen

  2003cited by this paper
• Botulinum toxin for the treatment of musculoskeletal pain and spasm

  2002cited by this paper
• Botulinum and tetanus neurotoxins: structure, function and therapeutic utility.

  2002cited by this paper
• Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study.

  2002cited by this paper
• Possible Mechanisms for the Effects of Botulinum Toxin on Pain

  2002cited by this paper
• The use of botulinum toxin for the treatment of chronic facial pain.

  2002cited by this paper
• The role of gustatory flushing in Frey's syndrome and its treatment with botulinum toxin type A

  2002cited by this paper
• Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia.

  2002cited by this paper
• A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia

  2002cited by this paper
• Inhibition of Release of Neurotransmitters from Rat Dorsal Root Ganglia by a Novel Conjugate of a Clostridium botulinumToxin A Endopeptidase Fragment and Erythrina cristagalliLectin*

  2002cited by this paper
• Retargeted clostridial endopeptidases: Inhibition of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain

  2002cited by this paper
• A Focused Review on the Use of Botulinum Toxins for Neuropathic Pain

  2002cited by this paper
• Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles.

  2001cited by this paper
• Review of botulinum toxin type A and its clinical applications in migraine headache

  2001cited by this paper
• Remote F-wave changes after local botulinum toxin application.

  2001cited by this paper
• Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes.

  2001cited by this paper
• Pharmacology and immunology of botulinum toxin serotypes

  2001cited by this paper
• [Reduction of pain and muscle spasms by botulinum toxin A].

  2001cited by this paper
• The use of botulinum toxin-A in the treatment of patients with fibromyalgia.

  2001cited by this paper
• Interventional approaches to the management of myofascial pain syndrome

  2001cited by this paper
• Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects

  2001cited by this paper
• Treating hyperhidrosis. Surgery and botulinum toxin are treatments of choice in severe cases.

  2000cited by this paper
• A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm

  2000cited by this paper
• Botulinum toxin type-A treatment in spastic paraparesis: a neurophysiological study.

  2000cited by this paper
• Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia

  2000cited by this paper
• Inhibition of Vesicular Secretion in Both Neuronal and Nonneuronal Cells by a Retargeted Endopeptidase Derivative ofClostridium botulinum Neurotoxin Type A

  2000cited by this paper
• Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins.

  2000influential reference
• [Mechanisms of myofascial pain].

  2000cited by this paper
• Evidence for metabolic abnormalities in the muscles of patients with fibromyalgia

  2000cited by this paper
• [Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles].

  2000cited by this paper
• Management of spasticity associated pain with botulinum toxin A.

  2000cited by this paper
• Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals.

  1999cited by this paper
• Internalization and Proteolytic Action of Botulinum Toxins in CNS Neurons and Astrocytes

  1999cited by this paper
• Management of post-thoracotomy pseudoangina and myofascial pain with botulinum toxin.

  1999cited by this paper
• Botulinum toxin type A

  1999cited by this paper
• American College of Rheumatology

  1999cited by this paper
• Book Review: Myofascial Pain and Dysfunction: The Trigger Point Manual Volume 1 (2Nd Edition)

  1999cited by this paper
• Increased capsaicin-induced secondary hyperalgesia as a marker of abnormal sensory activity in patients with fibromyalgia.

  1998cited by this paper
• The corticomotor representation of upper limb muscles in writer's cramp and changes following botulinum toxin injection.

  1998cited by this paper
• Blink reflex recovery cycle in patients with blepharospasm unilaterally treated with botulinum toxin.

  1998cited by this paper
• A Randomized, Double‐Blind, Prospective Pilot Study of Botulinum Toxin Injection for Refractory, Unilateral, Cervicothoracic, Paraspinal, Myofascial Pain Syndrome

  1998cited by this paper
• Hyperexcitability in fibromyalgia.

  1998cited by this paper
• Fibromyalgia is not a muscle disorder.

  1998cited by this paper
• Guidelines for the therapeutic use of botulinum toxin in movement disorders

  1997influential reference
• Dose-dependent, central effects of botulinum neurotoxin type A

  1997cited by this paper
• Possible deficiencies of pain modulation in fibromyalgia.

  1997cited by this paper
• Botulinum toxin in upper limb spasticity: study of reciprocal inhibition between forearm muscles

  1997cited by this paper
• Botulinum toxin does not reverse the cortical dysfunction associated with writer's cramp. A PET study.

  1997cited by this paper
• Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult‐onset spasticity

  1997cited by this paper
• Long-latency reflexes of hand muscles in idiopathic focal dystonia and their modification by botulinum toxin.

  1997cited by this paper
• Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia

  1997cited by this paper
• Peripheral CGRP release as a marker for neurogenic inflammation: a model system for the study of neuropeptide secretion in rat paw skin

  1997cited by this paper
• DYSBOT: A single‐blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1

  1997cited by this paper
• Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group.

  1997influential reference

• Treatment of myofascial pain and dysfunction using botulinum toxin A: a prospective study

  2024cites this paper
• Parietal abdominal pain with lower leg discrepancy: a case report

  2024cites this paper
• Schmerzen bei zervikaler Dystonie

  2024cites this paper
• Vulvodynia: A practical guide in treatment strategies

  2023cites this paper
• L’amnésie post-traumatique réflexe : la douleur, un modèle de tenségrité biologique ?

  2023cites this paper
• Intramuscular injections of botulinum toxin for the treatment of upper back myofascial pain syndrome: A systematic review of randomized controlled trials

  2023cites this paper
• Botulinum toxin application in erector spinae blockade for the management of myofascial syndrome in patients with fibromyalgia: A case series

  2022cites this paper
• The efficacy of botulinum toxin A treatment for tension-type or cervicogenic headache: a systematic review and meta-analysis of randomized, placebo-controlled trials

  2021cites this paper
• Temporomandibular Disorders

  2021cites this paper
• Acral Necrosis in a COVID-19-Infected Man Treated with Botulinum Toxin Type A

  2021cites this paper
• Bruksizmde Botulinum Toksini Etkinliğinin Değerlendirilmesi

  2021cites this paper
• The Use of Botulinum Toxin A as an Adjunctive Therapy in the Management of Chronic Musculoskeletal Pain: A Systematic Review with Meta-Analysis

  2021cites this paper
• Effect of multiple injections of botulinum toxin into painful masticatory muscles on bone density in the temporomandibular complex

  2020cites this paper
• Botulinum Toxin A as a Treatment for Provoked Vestibulodynia: A Randomized Controlled Trial.

  2020cites this paper
• The Effect of Intradermal Botulinum Toxin a injections on painful diabetic polyneuropathy.

  2020cites this paper
• Treatment of Vulvodynia: Pharmacological and Non-Pharmacological Approaches

  2019cites this paper
• The effectiveness of Clostridium botulinum toxin A (Dysport®, AbobotulinumtoxinA) in the management of temporomandibular dysfunction (TMD) and a small number of other maxillofacial conditions; an open cohort study

  2018cites this paper
• Pain in focal dystonias - A focused review to address an important component of the disease.

  2018cites this paper
• Use of botulinum toxin type a in temporomandibular disorder

  2017cites this paper
• 40 – Diagnosis and Treatment of Complex Regional Pain Syndrome

  2017cites this paper
• Challenges to develop novel anti-inflammatory and analgesic drugs.

  2017cites this paper
• Does Adjunctive Botulinum Toxin A Reduce Pain Scores When Combined With Temporomandibular Joint Arthroscopy for the Treatment of Concomitant Temporomandibular Joint Arthralgia and Myofascial Pain?

  2017cites this paper
• Botulinum Toxin Treatment for Nocturnal Calf Cramps in Patients With Lumbar Spinal Stenosis: A Randomized Clinical Trial.

  2017cites this paper
• Botulinum Toxin: Dentistry Insight.

  2016cites this paper
• Bradykinin Induces TRPV1 Exocytotic Recruitment in Peptidergic Nociceptors

  2016cites this paper
• Long‐term assessment of effectiveness and quality of life of OnabotulinumtoxinA injections in provoked vestibulodynia

  2016cites this paper
• Toxina botulínica: uma nova opção para o tratamento da neuralgia pós-herpética?

  2014cites this paper
• Myofascial pain syndrome treatments.

  2014cites this paper
• Botulinum Toxin Type A in the treatment of myofascial pain related to masticatory muscles

  2014cites this paper
• Toxina Botulínica Tipo A no tratamento da dor miofascial relacionada aos músculos da mastigação Botulinum Toxin Type A in the treatment of myofascial pain related to masticatory muscles

  2014cites this paper
• Jaw muscles myofascial pain and botulinum toxin *

  2013cites this paper
• Therapeutic efficacy and safety of botulinum toxin type A in trigeminal neuralgia: a systematic review

  2013cites this paper
• Comparative evaluation of the potency and antigenicity of two distinct BoNT/A-derived formulations

  2013cites this paper
• Dor miofascial dos músculos da mastigação e toxina botulínica

  2013cites this paper
• Nociceptive pathway function is normal in cervical dystonia: a study using laser-evoked potentials

  2012cites this paper
• Neurophysiological background for physical therapies in fibromyalgia.

  2012cites this paper
• Intramuscular botulinum toxin A (BtxA) in complex regional pain syndrome.

  2011cites this paper
• 14 – Botulinum Toxin Injections in Myofascial Pain Disorders

  2011cites this paper
• Efectos de la toxina botulínica A (Botox®) intraarticular en la artrosis de rodilla avanzada

  2011cites this paper
• The Effectiveness and Economical Benefits of Cosmetic Treatments and Procedures Versus Natural Treatments and Life Style Changes

  2011cites this paper
• Dysport® for the treatment of myofascial back pain: Results from an open-label, Phase II, randomized, multicenter, dose-ranging study

  2011cites this paper
• Efficacy of high doses of botulinum toxin A for treating provoked vestibulodynia

  2011cites this paper
• Intramuscular botulinum toxin in complex regional pain syndrome: case series and literature review.

  2011cites this paper
• Evidence for Anterograde Transport and Transcytosis of Botulinum Neurotoxin A (BoNT/A)

  2011cites this paper
• Re-Engineering Clostridial Neurotoxins for the Treatment of Chronic Pain

  2010influential citation
• Treatment of scapula dyskinesia with botulin toxin: two case reports

  2010cites this paper
• Effects of A2 type botulinum toxin on spontaneous miniature and evoked transmitter release from the rat spinal excitatory and inhibitory synapses.

  2010cites this paper
• Quantification of potency of neutralizing antibodies to botulinum toxin using compound muscle action potential (CMAP).

  2010cites this paper
• Writer's cramp: A potential early feature of Huntington's disease

  2010cites this paper
• Botulinic Toxin Type A: action mechanism

  2009influential citation
• Novel GFAP Mutation in Patient with Adult-Onset Alexander Disease Presenting with Spastic Ataxia

  2009influential citation
• Botulinum toxin in painful tardive dyskinesia.

  2009cites this paper
• Toxina Botulínica do Tipo A: mecanismo de ação

  2009cites this paper
• Novel GFAP Mutation in Patient with Adult-Onset Alexander Disease Presenting with Spastic Ataxia

  2009influential citation
• Novel GFAP mutation in patient with adult‐onset Alexander disease presenting with spastic ataxia

  2009influential citation